Abstract X-linked dominant chondrodysplasia punctata (CDPX2 or Conradi-Hünermann-Happle syndrome, MIM #302960) is caused by mutations in the EBP gene. Affected female patients present with Blaschkolinear ichthyosis, coarse hair or alopecia, short stature, and normal psychomotor development. The disease is usually lethal in boys. Nevertheless, few male patients have been reported; they carry a somatic mosaicism in EBP or present with Klinefelter syndrome. Here, we report CDPX2 patients belonging to a three-generation family, carrying the splice variant c.301 + 5 G > C in intron 2 of EBP. The grandfather carries the variant as mosaic state and presents with short stature and mild ichthyosis. The mother also presents with short stature and mild ichthyosis and the female fetus with severe limb and vertebrae abnormalities and no skin lesions, with random X inactivation in both. This further characterizes the phenotypical spectrum of CDPX2, as well as intrafamilial variability, and raises the question of differential EBP mRNA splicing between the different target tissues.
Introduction
X-linked dominant chondrodysplasia punctata (CDPX2, MIM #302960), also known as Conradi-Hünermann-Happle syndrome, is a rare heterogeneous disorder characterized by asymmetrical bone defects including epiphyseal stippling, shortening of limbs, kyphoscoliosis, neonatal ichthyosis with follicular atrophoderma later in life, patchy alopecia or coarse hair, cataracts, and craniofacial defects [1, 2] . Affected patients usually present with short stature but normal psychomotor development. CDPX2 was initially described in females and is considered to be lethal early in pregnancy in hemizygous males. Most male patients described have carried somatic mosaicism [3, 4] . One patient with Klinefelter syndrome has also been reported [5] . High clinical variability has been reported in females, from severe prenatally diagnosed cases to mildly affected adults with a phenotype limited to skin, suggested to be caused by skewed X-inactivation [6, 7] or somatic mosaicism [8] .
CDPX2 is caused by mutations in the EBP gene (chromosome Xp11.23) encoding the emopamil-binding protein, which plays a key role in the last steps of cholesterol biosynthesis [9, 10] . Diagnosis is suspected in patients exhibiting elevated levels of cholesterol precursors in plasma and involved tissues. Sequencing EBP gene confirms the diagnosis. To date, more than 70 EBP mutations have been reported. Genotype to phenotype correlation remains uncertain [11] .
Here, we report the observation of a severely affected female fetus revealing a family history of CDPX2 with a mildly affected mother and grandfather.
Patients and methods

Patients
Patient II.2, a 22 weeks of gestation (WG) pregnant woman, was referred for fetal bone anomalies detected on the second ultrasound examination of her uneventful pregnancy (Fig. 1) . The fetus (III.1) presented with severe shortening of long bones of upper and lower limbs, multiple epiphyseal stippling and vertebral abnormalities with spinal puzzle. Given the diagnosis of severe punctuated chondrodysplasia, the functional risk to the child and the initial hypothesis of peroxysomal disease, the pregnancy was terminated at 24 WG. Fetal autopsy revealed an asymmetrical rhizomelic shortening of the limbs without skin abnormalities, visceral malformation, or facial dysmorphism. Skeletal X-rays showed multiple and symmetrical bone punctuations of the tarsus, the carpus, the ribs, the knee-caps, and the spine, associated to vertebral puzzle (Fig. 1) . The karyotype (46, XX) was normal. Peroxysomal disease has been excluded after the termination with normal very long chain fatty acids on fetal plasma and normal DHAP-AT on cultured amniocytes. The diagnosis of CDPX2 was confirmed on fetal tissue.
Patient II.2 presented with short stature (150 cm), xerosis, patchy alopecia of the scalp and coarse hair. Musculoskeletal examination was normal (Fig. 1) .
Family history showed that Patient I-1 presented with low height (165 cm), lower limb asymmetry, fluctuating asymmetrical and linear ichthyosis associated to two patches of scalp alopecia (Fig. 1) .
Informed consent was obtained from both patients. Genomic DNA was extracted from peripheral blood for individual II.2, from peripheral blood and skin biopsy for individual I.1, and from fetal lung for the fetus (III.1).
Sterol analysis
Cholesterol, 7 dehydrocholesterol (7DHC; cholest-7-en-3β-ol), lathosterol, epicoprostanol (5α-cholestan-3β-ol) and desmosterol (cholesta-5,24-dien-3β-ol) were obtained from Sigma (Saint-Louis, MO, USA). Solvents of the analytical grade were purchased from Sigma. The silylation reagent (Regisil) was obtained from Interchim (Montluçon, France).
A volume of 200 μl of fresh plasma was mixed in 5 ml of the solvent mixture chloroform/methanol 2/1 (v/v) containing the internal standard (epicoprostanol). Lipids were partitioned in chloroform after addition of saline and saponified by methanolic potassium hydroxide (0.5 N, 60°C, 15 min). Released fatty acids were methylated by BF3-methanol (12%, 60°C, 15 min) to prevent interference with the chromatography of sterols. Sterols were reextracted in hexane and silylated as described previously [12] . The trimethylsilylether derivatives of the sterols were separated by gas liquid chromatography (Hewlett-Packard 6890 Series) in a medium polarity capillary column provided by Restesk (Evry, France) (RTX-65, (65% diphenyl 35% dimethyl polysiloxane), length 30 m, diameter 0.32 mm, film thickness 0.25 μm). Sterols were identified by comparison of the mass spectra with the NIST library. The mass spectrometer (Agilent 5875 inert XL Mass Selective Detector, Agilent Technologies France) in series with the GC was set up for the detection of the positive fragment ions. Fragment ions were produced in the electron impact mode at 70 eV. The sterols were identified in the scanning mode and quantified by selective monitoring of the prominent ions after normalization with the internal standard epicoprostanol and calibration with weighed standards.
Molecular analysis
Following informed consent for genetic testing, genomic DNA was extracted from peripheral blood leucocytes by a phase exchange method (Puregene, Qiagen) and quantified with Spectrophotometer Nanodrop (Shimadzu). The entire coding region of EBP gene and flanking intronic sequences were amplified by polymerase chain reaction (PCR) using previously described primers [3] with a modification for exon 2: 5′-TTCGGTCCATTTACATTTCTCA-3′ (forward) to explore the intron/exon junction. Cycling conditions were as follows: 35 cycles at 95°C for 5 min, 95°C for 30 s, 60°C for 30 s, and 72°C for 45 s and extension at 72°C for 7 min. PCR products were sequenced for both strands on an automated sequencer (3500XL Dx, Applied Biosystems).
Results are reported with exons numbered according to NG_007452.1 accession.
X inactivation analysis
Analysis of leukocyte X chromosome inactivation at the HUMARA locus was performed as previously described [13] . Briefly, genomic DNA was digested using the methylation-sensitive enzyme HhaI and HpaII. Undigested and digested DNA were then subjected to PCR amplification of the highly polymorphic CAG-repeat sequence in the human androgen receptor (HUMARA), with specific fluorescent primers. PCR products were analyzed on an automated DNA sequencer (ABI PRISM 3130 DNA sequencer, Life technologies). A control DNA with known skewed X inactivation was also tested in the same experiment.
Splice-site predictions
The predicted effect of the variant on RNA splicing was studied using the five tools combined in the splicing prediction module of the Alamut Visual Software (V2.7, Interactive Biosoftware, Rouen, France).
Splicing minigene reporter assay
The splicing minigene assay was adapted from the method described by Gaildrat [14] . Wild-type genomic segments corresponding to the exon 2 of EBP (NM_006579.2) with flanking intronic sequences (701 bp) were amplified by PCR from control genomic DNA (Q5 High-Fidelity DNA Polymerase, NEB). The primer sequences and PCR conditions used are available upon request. The PCR product was cloned into the pCAS2 vector digested with BamHI and MluI enzymes. Plasmids were purified and sequenced on the inserted region. Mutant construct containing the c.301 + 5 G > C variant was generated by using the Q5 site-directed mutagenesis kit (NEB) according to the manufacturer's instructions. Purified plasmids were sequenced to confirm the site-directed mutagenesis. Normal and mutant pCAS2 minigenes were transfected into HeLa cells using Fugene 6 transfection reagent (Promega) which were harvested 24 h later. Total RNA was isolated using the NucleoSpin RNA Plus kit (Macherey-Nagel). Oligo(dT) primers and the ProtoScript II First Strand cDNA Synthesis Kit (NEB) was used to synthesize cDNA, according to the manufacturer's instructions. RT-PCR was performed using primers located in exons A and B of the pCAS2 vector. The exons A et B refer to the pCAS2 vector as it is shown in Fig. 2a . Amplified products were visualized by GelRed staining (Biotium) after electrophoresis on 1% agarose gel and Sanger sequenced to describe splicing variations.
Tissue mRNA analysis
Total RNA was extracted from fetal lung using the NucleoSpin RNA Plus kit (Macherey-Nagel) and cDNA was generated following the instructions described above. The primer sequences and RT-PCR conditions used are available upon request. RT-PCR products were analyzed on 1% agarose gel electrophoresis and Sanger sequenced.
Database submission
Clinical data of fetus and gene variant in EBP were submitted at www.LOVD.nl/EBP with ID 00155196.
Results
Biochemical diagnosis
Sterol analysis was performed on fetal tissue, and elevated hepatic 8-lathosterol and 8-dehydrocholesterol with a (8-Lathosterol + 8-dehydrocholesterol)/cholesterol ratio of 0.0829 was found, consistent with a deficit in the last steps of cholesterol biosynthesis, and suggesting the diagnosis of X-Linked Chondrodysplasia Punctata.
Sterol analysis was also performed in blood of the mother and of the maternal grandfather showing sterol ratios of 0.005 and 0.004, respectively, compatible with CDPX2 in those two individuals.
Molecular diagnosis
A heterozygous variation was identified by Sanger sequencing in EBP, NM_006579.2:c.301 + 5 G > C (genomic reference sequence NG_007452.1:g.7302 G > C) (Supplementary figure) in the fetal tissue DNA. Familial analysis revealed that the variant was inherited from the mother and was also present as a mosaic variant in the maternal grandfather with an allelic fraction of around 20% (Fig. 1) . Skin biopsies from grandfather confirmed the presence of the variation at mosaic state with a mutated allelic fraction of around 50%, both in normal and affected skin. Prediction of an impact on splicing was tested with the splicing prediction module of the Alamut® Visual Software. An abolishment of the wild-type splice site was highlighted by four of the five tools and a significant alteration in the score of the splice site strength was predicted by the latest tool (data not shown).
X inactivation analysis
X inactivation was random in individuals II.2 and III.1, in the blood and fetal cells, respectively.
Splicing functional assay by minigene constructions
A splicing pCAS2 reporter minigene assay was designed, containing exon 2 of EBP with part of its flanking intronic sequences. After transfection into HeLa cells, splicing for both wild-type and c.301 + 5 G > C mutant constructs were evaluated by RT-PCR analysis and Sanger sequencing. Consistently with the in silico predictions, no transcript retaining exon 2 was detected in presence of the splice variant. In the wild-type context, a predominant band corresponding to normal splicing of the exon 2 was detected. Some minor bands were identified on the electrophoresis gel but were not highlighted in Sanger sequencing, suggesting an artefact from the in vitro model (Fig. 2a) .
Tissue mRNA analysis
The effect of the variant c.301 + 5 G > C was tested using RNA extracted from fetal lung tissue. Gel electrophoresis of RT-PCR showed two bands for fetal tissue (data not shown). The first corresponds to normal splicing whereas the second corresponds to exon 2 skipping (Fig. 2b) . The healthy control showed predominantly a band corresponding to normal splicing of EBP (data not shown).
Discussion
Severe CDPX2 presentations are rare in women. To date, only 15 female cases with prenatal presentation have been reported [7, [15] [16] [17] [18] .
The propositus was a severely affected female fetus with a variant inherited from her mother presenting only mild CDPX2 symptoms. This post-zygotic nucleotidic change occurred during the pregnancy of the maternal grandfather of the proband (Patient I-1). The grandfather was also mildly affected and presented with phenotypic differences from his siblings. Unlike her mother and grandfather, the fetus showed mostly skeletal features and no skin lesions at the time of termination, while ichthyosis could have been noticed as early as 18 WG [7] . Yet, skin involvement may have developed during the following weeks of pregnancy or even in the postnatal period.
Patient II.2 also had two early miscarriages, suggesting early male lethality of this EBP variant, although other causes cannot be excluded.
Anticipation, phenotypic variation and incomplete penetrance have previously been described as typical features of CDPX2 [11, 15, 19, 20] . Some cases were explained by skewed X inactivation [19, 21] although this has not been confirmed in several other family cases [15] . Moreover, the absence of skewed X inactivation in the studied tissue, does not exclude skewed X inactivation in the involved cell types such as cartilage or skeletal tissue [15, 22] .
The c.301 + 5 G > T variant has been previously described in dbSNP as likely benign (rs886038570), but without phenotypic precision. It was predicted to abolish the 3ʹ splice site of exon 2. Functional studies by RNA analysis and minigene assays consistently found skipping of exon 2 consecutive to the variant. It should be noted that EBP spans 5 exons, four of which are coding with ATG start codon at the beginning of exon 2, which cause a null allele in this case of abnormal splicing.
Interestingly, this family presented with rather severe skeletal manifestations, as this was the only symptom in the fetus, and both mother and grandfather presented with short stature compared to their unaffected relatives. They had relatively mild cutaneous symptoms, whereas in a previous cohort, eight out of nine fetuses presented with precocious ichthyosis. The pregnancy was terminated earlier than 18 WG for the ninth fetus, at a time when epidermic keratinization had not yet occurred. In the same cohort, seven fetuses out of nine had asymmetric shortening of the long bones, and five had bowing of the long bones [7] . Absence of cutaneous abnormality could be secondary to differential splicing in different target tissues with, for this variant, less exon skipping in the ectodermic tissue and more in mesodermic tissue.
Although CDPX2 is considered lethal in males, some living patients have been described [23] . For most of them, molecular diagnosis had not been performed. BarbozaCerda et al. suggested that clinical variability of CDPX2 in males was part of a continuous phenotypic spectrum [24] . While mutations leading to absent EBP protein can cause intra-uterine lethality in male fetuses, somatic mosaicism [3, 4] or, more rarely, functional X inactivation, such as was described in a 47,XXY patient [5] could cause phenotypic features similar to CDPX2-affected females.
Also, a distinct non-lethal syndrome linked to EBP hypomorphic alleles was described at the hemizygous, nonmosaic state in males [23] [24] [25] [26] . Patients present with neurological defects and mental retardation. Arnold et al. speculated that residual isomerase activity allowed survival of male fetuses and proposed the name MEND syndrome, for Male EBP disorder with Neurological Defects (MIM #300960) [27, 28] .
We could thus postulate that a complete enzymatic deficit in a cell population caused by a null allele, as seen in CPDX2, may result in the phenotype through accumulation of toxic cholesterol precursors, for example, whereas residual enzymatic activity, such as occurs in MEND syndrome, could cause a neurodevelopmental syndrome without skeleton abnormalities. Interindividual variability in CDPX2 would then be secondary to different degrees of mosaicism (in males and females) or different X inactivation patterns (in females), or even variable tolerance to sterol precursor toxicity. Considering the numerous genes involved in the cholesterol biosynthesis, undiagnosed variants in related EBP genes may be implicated on the observed variability. However, to our knowledge, no single modifier gene has been identified, suggesting either a heterogeneous, patient-specific mechanism, or, more likely, involvement of variants in several genes in a polygenic model. Unfortunately, because of lack of fetal material, we could not verify this hypothesis by conducting a broader analysis, such as whole exome or whole genome sequencing.
As a conclusion, we described a family carrying an EBP variant leading to a splicing alteration, responsible for CDPX2 in three generations: one mildly affected male carrying the variant at a mosaic state, his daughter who only presented with moderate short stature and xerosis, and a severely affected female fetus. We cannot exclude intrafamilial variability secondary to skewed X inactivation in target tissues other than the ones studied in mother and child, but it may also be caused by anticipation, as previously postulated. The predominant skeletal phenotype compared with more classical cutaneous features suggests variability in EBP mRNA splicing efficiency in different target tissues.
